J. Rubio-Briones, A. Borque-Fernando, L. M. Esteban Escaño, A. Wong, A. Guijarro Cascales, E. Gómez Gómez, J. M. Gil Fabra, F. Sanguedolce, F. Gomez-Veiga, P. A. López González, A. Plata Bello, N. Rodríguez García, M. Montesino Semper, J. F. Suárez Novo, R. Hajianfar, L. l. Fumadó Ciutat, A. González Alfaro, J. M. Duarte Ojeda, A. Bono Ariño, C. Quicios Dorado, A. Loizaga Iriarte, G. García Fadrique, J. M. Giménez Bachs, S. García Barreras, Y. Pallas Costa, A. Vilaseca Cabo, M. Rodrigo Aliaga, F. Campanario Pérez, P. Servián, J. M. Campá Bortoló, M. Soto Delgado, J. M. Rodríguez de Ledesma, C. Sánchez Rodríguez, V. Chantada Abal, Y. E. Hernández Martínez, B. Herrera Imbroda, P. Dolezal, J. Gual Frau, P. Medrano Llorente, J. Moreno Jiménez, J. S. Serrano Uribe, C. B. Congregado Ruiz, A. Reyes, T. Fernández Aparicio, J. García Rodríguez, M. Cuadras Solé, A. García Seguí, J. J. Pacheco Bru, J. Mayor de Castro, A. Mira Moreno, J. L. Molina Suárez
{"title":"西班牙前列腺癌主动监测的真实世界证据期中考试结果","authors":"J. Rubio-Briones, A. Borque-Fernando, L. M. Esteban Escaño, A. Wong, A. Guijarro Cascales, E. Gómez Gómez, J. M. Gil Fabra, F. Sanguedolce, F. Gomez-Veiga, P. A. López González, A. Plata Bello, N. Rodríguez García, M. Montesino Semper, J. F. Suárez Novo, R. Hajianfar, L. l. Fumadó Ciutat, A. González Alfaro, J. M. Duarte Ojeda, A. Bono Ariño, C. Quicios Dorado, A. Loizaga Iriarte, G. García Fadrique, J. M. Giménez Bachs, S. García Barreras, Y. Pallas Costa, A. Vilaseca Cabo, M. Rodrigo Aliaga, F. Campanario Pérez, P. Servián, J. M. Campá Bortoló, M. Soto Delgado, J. M. Rodríguez de Ledesma, C. Sánchez Rodríguez, V. Chantada Abal, Y. E. Hernández Martínez, B. Herrera Imbroda, P. Dolezal, J. Gual Frau, P. Medrano Llorente, J. Moreno Jiménez, J. S. Serrano Uribe, C. B. Congregado Ruiz, A. Reyes, T. Fernández Aparicio, J. García Rodríguez, M. Cuadras Solé, A. García Seguí, J. J. Pacheco Bru, J. Mayor de Castro, A. Mira Moreno, J. L. Molina Suárez","doi":"10.1002/cam4.71173","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>In this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1–3: 43.78–85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression-free survival, metastasis-free survival, and active treatment-free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Midterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov identifier: NCT02865330</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 17","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71173","citationCount":"0","resultStr":"{\"title\":\"Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results\",\"authors\":\"J. Rubio-Briones, A. Borque-Fernando, L. M. Esteban Escaño, A. Wong, A. Guijarro Cascales, E. Gómez Gómez, J. M. Gil Fabra, F. Sanguedolce, F. Gomez-Veiga, P. A. López González, A. Plata Bello, N. Rodríguez García, M. Montesino Semper, J. F. Suárez Novo, R. Hajianfar, L. l. Fumadó Ciutat, A. González Alfaro, J. M. Duarte Ojeda, A. Bono Ariño, C. Quicios Dorado, A. Loizaga Iriarte, G. García Fadrique, J. M. Giménez Bachs, S. García Barreras, Y. Pallas Costa, A. Vilaseca Cabo, M. Rodrigo Aliaga, F. Campanario Pérez, P. Servián, J. M. Campá Bortoló, M. Soto Delgado, J. M. Rodríguez de Ledesma, C. Sánchez Rodríguez, V. Chantada Abal, Y. E. Hernández Martínez, B. Herrera Imbroda, P. Dolezal, J. Gual Frau, P. Medrano Llorente, J. Moreno Jiménez, J. S. Serrano Uribe, C. B. Congregado Ruiz, A. Reyes, T. Fernández Aparicio, J. García Rodríguez, M. Cuadras Solé, A. García Seguí, J. J. Pacheco Bru, J. Mayor de Castro, A. Mira Moreno, J. L. Molina Suárez\",\"doi\":\"10.1002/cam4.71173\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Patients and Methods</h3>\\n \\n <p>In this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1–3: 43.78–85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression-free survival, metastasis-free survival, and active treatment-free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Midterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov identifier: NCT02865330</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 17\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71173\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71173\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results
Patients and Methods
In this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.
Results
A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1–3: 43.78–85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression-free survival, metastasis-free survival, and active treatment-free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively.
Conclusions
Midterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
